Ixekizumab Superior to Adalimumab in Joint, Skin Improvement in Psoriatic Arthritis
Ixekizumab demonstrated superiority to adalimumab in achieving simultaneous joint and skin improvement in biologic-naive patients with active psoriatic arthritis, according to data from the phase 3b/4 SPIRIT Head-to-Head (H2H) study.